MVASI™ – The biosimilar option to Avastin®

Providing ophthalmic solutions to retinologists and ophthalmologists with confidence in quality has been an essential service we provide at Compound Preferred. With the vast experience from our Pharmacist in Charge and Quality Assurance and Regulatory Affairs Manager, we ensure our products are created in an FDA-approved ISO 8 room, and USP testing is conducted.

In an effort to provide even more cost-effective products, we are not only aliquoting Avastin but producing an Avastin biosimilar, MVASI. 

Play Video

Facts about MVASI

MVASI and Avastin have the same inactive ingredients

Various insurance formularies accept MVASI

MVASI is less expensive than Avastin

References

Contact Bretagne Pullens to learn more.

Filling the 503A Gap

While 503A compounding pharmacies fulfill a vital need for patient-specific compounded products, 503B outsourcing facilities fulfill another need to the medical community. 503B outsourcing facilities